FINNENCE ▪ THE WIRE FILE
THE WIRE · № 69952
News■ Unclear/unknown
Medical device maker Centinel Spine discloses revenue rise in US IPO filing
KINDNews
DIRECTION■ Unclear/unknown
SOURCES3
ENTITIES1
STORY SIZE2 RECORDS
FIRST SEEN2026-10-07 21:13 UTC
LAST UPDATE2026-10-07 21:24 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A medical-device IPO filing shows continued healthcare capital-markets activity, though the issuer is small.
Small medtech IPO adds to listing pipeline
CATALYST TO WATCH
IPO pricing and debut
MAIN RISK
Small deal, limited market impact
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 2 TIMES · FIRST 2026-10-07 21:13 UTC · LAST 2026-10-07 21:24 UTC2026-10-07 21:13 UTCNewsMedical device maker Centinel Spine discloses revenue rise in US IPO filingCURRENT RECORD
2026-10-07 21:24 UTCNewsCNTL IPO News - Spinal implant developer Centinel Spine files for a $100 million IPO
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.2026-10-07 21:31 UTC
Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.2026-10-07 21:31 UTC
→CORRELATIONshares Healthcare
Okami Medical Receives Expanded Indication for the LOBO Vascular Occluder2026-10-07 21:51 UTC
Okami Medical Receives Expanded Indication for the LOBO Vascular Occluder2026-10-07 21:51 UTC
→CORRELATIONshares Healthcare
CNTL IPO News - Spinal implant developer Centinel Spine files for a $100 million IPO2026-10-07 21:24 UTC
CNTL IPO News - Spinal implant developer Centinel Spine files for a $100 million IPO2026-10-07 21:24 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne — Sagimet Biosciences Inc.2026-10-07 12:00 UTC
New Phase 3 trial: Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne — Sagimet Biosciences Inc.2026-10-07 12:00 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate — Grifols Biologicals, LLC2026-10-07 12:00 UTC
Phase 3 results posted: Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate — Grifols Biologicals, LLC2026-10-07 12:00 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers — Sanofi2026-10-07 12:00 UTC
Phase 3 results posted: Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers — Sanofi2026-10-07 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.